MA28113A1 - 2-(3,4-dimethylphenyl)-4-([2-hydroxy-3'(1h-tetrazol-5-yl) biphenyl-3-yl]-hydrazono]-5-methyl-2,4-dihydropyrazol-3-one choline - Google Patents

2-(3,4-dimethylphenyl)-4-([2-hydroxy-3'(1h-tetrazol-5-yl) biphenyl-3-yl]-hydrazono]-5-methyl-2,4-dihydropyrazol-3-one choline

Info

Publication number
MA28113A1
MA28113A1 MA28969A MA28969A MA28113A1 MA 28113 A1 MA28113 A1 MA 28113A1 MA 28969 A MA28969 A MA 28969A MA 28969 A MA28969 A MA 28969A MA 28113 A1 MA28113 A1 MA 28113A1
Authority
MA
Morocco
Prior art keywords
hydrazono
tetrazol
dimethylphenyl
biphenyl
hydroxy
Prior art date
Application number
MA28969A
Other languages
English (en)
Inventor
Brook S Christopher
Ping J Li-Jen
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of MA28113A1 publication Critical patent/MA28113A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

Sel de choline de 2-(3,4-diméthylphényl)-4- {[2-hydroxy-3'-(1H-tétrazole-5-yl)biphényl-3-yl] hydrazono}-5-méthyl-2,4-dihydropyrazole-3-one Agent mimétique de thrombopoiétine amélioré, consistant en le sel de choline de 2-(3,4-diméthylphényl)-4-{[2-hydroxy-3'-(1H-tétrazole-5-yl)biphényl-3-yl]-hydrazono}-5-méthyl-2,4-dihydropyrozole-3-one.
MA28969A 2003-10-22 2006-04-25 2-(3,4-dimethylphenyl)-4-([2-hydroxy-3'(1h-tetrazol-5-yl) biphenyl-3-yl]-hydrazono]-5-methyl-2,4-dihydropyrazol-3-one choline MA28113A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51348103P 2003-10-22 2003-10-22

Publications (1)

Publication Number Publication Date
MA28113A1 true MA28113A1 (fr) 2006-08-01

Family

ID=34549283

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28969A MA28113A1 (fr) 2003-10-22 2006-04-25 2-(3,4-dimethylphenyl)-4-([2-hydroxy-3'(1h-tetrazol-5-yl) biphenyl-3-yl]-hydrazono]-5-methyl-2,4-dihydropyrazol-3-one choline

Country Status (19)

Country Link
US (1) US7666857B2 (fr)
EP (1) EP1684748A4 (fr)
JP (1) JP2007509159A (fr)
KR (1) KR20060095761A (fr)
CN (1) CN1897937B (fr)
AR (1) AR046188A1 (fr)
AU (1) AU2004285462B2 (fr)
BR (1) BRPI0415704A (fr)
CA (1) CA2543216A1 (fr)
IL (1) IL174924A0 (fr)
IS (1) IS8461A (fr)
MA (1) MA28113A1 (fr)
MX (1) MXPA06004483A (fr)
NO (1) NO20062111L (fr)
NZ (1) NZ546463A (fr)
RU (1) RU2379297C2 (fr)
TW (1) TW200526638A (fr)
WO (1) WO2005041867A2 (fr)
ZA (1) ZA200602901B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CY2010012I2 (el) 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
MY142390A (en) 2002-05-22 2010-11-30 Glaxosmithkline Llc 3' - [(2z)-[1-(3,4-dimethylphenyl)-1,5- dihydro-3- methyl-5-0xo-4h-pyrazol-4- ylidene]hydrazino]-2' -hydroxy -[1,1' -biphenyl]-3-carboxylic acid bis-(monoethanolamine)
EP1622609A4 (fr) * 2003-04-29 2008-09-03 Smithkline Beecham Corp Procedes de traitement de maladies/lesions degeneratives
US20100004302A1 (en) * 2003-04-29 2010-01-07 Connie Erickson-Miller Methods for Treating Degenerative Diseases/Injuries
US20090048318A1 (en) * 2003-04-29 2009-02-19 Connie Erickson-Miller Methods for treating degenerative diseases/injuries
US20090143453A1 (en) * 2003-04-29 2009-06-04 Connie Erickson-Miller Methods for treating degenerative diseases/injuries
US20090298179A1 (en) * 2003-04-29 2009-12-03 Connie Erickson-Miller Methods For Treating Degenerative Diseases/Injuries
TW200526638A (en) 2003-10-22 2005-08-16 Smithkline Beecham Corp 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
US20070031373A1 (en) * 2005-08-04 2007-02-08 Carlos Lopez Reversal of Adult Onset Disorders with Granulocyte-Colony Stimulating Factors
WO2007044982A2 (fr) * 2005-10-13 2007-04-19 Smithkline Beecham Corporation Méthodes pour conserver l'efficacité de plaquettes pendant le stockage
US7879318B2 (en) 2006-01-23 2011-02-01 Mcw Research Foundation, Inc. Method of reducing the effects of ischemia by administration of a thrombopoietin receptor ligand
GB0603522D0 (en) * 2006-02-22 2006-04-05 Avidex Ltd Kinase inhibition
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
EP2434894B1 (fr) 2009-05-29 2016-08-31 Novartis AG Procédés d'administration de composés agonistes de la thrombopoïétine
RU2469763C1 (ru) * 2011-11-16 2012-12-20 Анатолий Степанович Дресвянкин Коньколыжи
EP3307722B1 (fr) * 2015-06-12 2021-08-04 GB006, Inc. Formes solides d'acide (z)-4-(5- ((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidène) méthyl)furanne-2-yl) benzoïque

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE193350C (fr)
US851444A (en) * 1905-11-13 1907-04-23 Agfa Ag Amido-oxy-sulfonic acid of phenylnaphthimidazol and process of making same.
GB779880A (en) 1953-02-27 1957-07-24 Ciba Ltd Functional derivatives of azo-dyestuffs containing sulphonic acid groups and processfor making them
GB826207A (en) 1956-07-23 1959-12-31 Bayer Ag ú´-ú´-dihydroxy-monoazo dyestuffs containing pyrrolidonyl residues and their metal complex compounds
US2950273A (en) * 1956-11-20 1960-08-23 Agfa Ag Process for the production of symmetrical and unsymmetrical azo compounds
US3366619A (en) * 1965-04-09 1968-01-30 Interchem Corp Disazo pyrazolone pigments
US4435417A (en) * 1981-02-20 1984-03-06 Gruppo Lepetit S.P.A. Antiinflammatory 3H-naphtho[1,2-d]imidazoles
ES523609A0 (es) * 1982-07-05 1985-03-01 Erba Farmitalia Procedimiento para preparar derivados n-imidazolilicos de compuestos biciclicos.
FI91869C (fi) * 1987-03-18 1994-08-25 Tanabe Seiyaku Co Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi
US4880788A (en) * 1987-10-30 1989-11-14 Baylor College Of Medicine Method for preventing and treating thrombosis
WO1993017681A1 (fr) 1992-03-02 1993-09-16 Abbott Laboratories Antagonistes du recepteur d'angiotensine ii
GB9205320D0 (en) * 1992-03-11 1992-04-22 Ici Plc Anti-tumour compounds
IL109570A0 (en) 1993-05-17 1994-08-26 Fujisawa Pharmaceutical Co Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
EP0638617A1 (fr) 1993-08-13 1995-02-15 Ciba-Geigy Ag Sels de pigments
EP0661170B1 (fr) * 1993-12-28 1998-09-02 Dai Nippon Printing Co., Ltd. Feuille pour transfert thermique
US5482546A (en) * 1994-03-30 1996-01-09 Canon Kabushiki Kaisha Dye, ink containing the same, and ink-jet recording method and instrument using the ink
FR2725987B1 (fr) * 1994-10-19 1997-01-10 Sanofi Sa Procede pour la preparation d'un derive de tetrazole sous deux formes cristallines et nouvelle forme cristalline de ce derive
RU2144533C1 (ru) * 1994-12-09 2000-01-20 Такеда Кемикал Индастриз, Лтд. Производные тетразола, способ их получения и фармацевтические композиции на их основе
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5746821A (en) * 1995-02-13 1998-05-05 Engelhard Corporation Pigment compositions
CN1966520B (zh) 1995-06-07 2012-07-11 葛兰素集团有限公司 结合血小板生成素受体的肽和化合物
US5622818A (en) * 1995-11-29 1997-04-22 Eastman Kodak Company Color photographic elements containing yellow colored magenta dye forming masking couplers
US5669967A (en) * 1996-05-30 1997-09-23 Engelhard Corporation Pigment compositions
US5932546A (en) * 1996-10-04 1999-08-03 Glaxo Wellcome Inc. Peptides and compounds that bind to the thrombopoietin receptor
SE9701398D0 (sv) 1997-04-15 1997-04-15 Astra Pharma Prod Novel compounds
GB9715830D0 (en) * 1997-07-25 1997-10-01 Basf Ag Reactive dyes containing piperazine
WO1999011262A1 (fr) 1997-09-02 1999-03-11 Roche Diagnostics Gmbh Ligands du recepteur mpl, leur procede de preparation, medicaments les contenant et leur utilisation pour le traitement et la prevention de la thrombocytopenie et l'anemie
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US20010016568A1 (en) * 1997-10-31 2001-08-23 Juan I. Luengo Novel metal complexes
DE19851389A1 (de) * 1998-11-07 2000-05-11 Dystar Textilfarben Gmbh & Co Gelbe Farbstoffmischungen von wasserlöslichen faserreaktiven Azofarbstoffen und ihre Verwendung
GC0000177A (en) 1998-12-17 2006-03-29 Smithkline Beecham Thrombopoietin mimetics
KR20020069183A (ko) 1999-07-26 2002-08-29 시오노기세이야쿠가부시키가이샤 트롬보포이에틴 작동성을 나타내는 의약 조성물
AU770564B2 (en) 1999-09-10 2004-02-26 Smithkline Beecham Corporation Thrombopoietin mimetics
AU771460B2 (en) 1999-09-24 2004-03-25 Smithkline Beecham Corporation Thrombopoietin mimetics
JP2003513965A (ja) 1999-11-05 2003-04-15 スミスクライン・ビーチャム・コーポレイション セミカルバゾン誘導体およびそれらのトロンボポエチン模倣物としての使用
EP1104674A1 (fr) * 1999-11-10 2001-06-06 Curacyte AG Colorants o-o'-dihydroxy azoiques dans des médicaments ayant une activité TPO-agoniste ou synergétique
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
US6436915B1 (en) 2000-04-07 2002-08-20 Kinetek Pharmaceuticals, Inc. Pyrazole compounds
US6214813B1 (en) * 2000-04-07 2001-04-10 Kinetek Pharmaceuticals, Inc. Pyrazole compounds
CY2010012I2 (el) * 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
JP2004520302A (ja) 2000-12-19 2004-07-08 スミスクライン・ビーチャム・コーポレイション トロンボポエチン模倣物
JP2004532614A (ja) 2000-12-21 2004-10-28 スミスクライン・ビーチャム・コーポレイション 金属キレート化アゴニストによる細胞膜受容体の活性化の調節
WO2002059099A1 (fr) 2001-01-26 2002-08-01 Shionogi & Co., Ltd. Composes cycliques presentant un agonisme envers le recepteur de thrombopoietine
MXPA03006510A (es) * 2001-01-26 2003-10-15 Shionogi & Co Compuestos halogenados que muestran agonismo del receptor de trombopoyetina.
EP1370252A4 (fr) 2001-03-01 2006-04-05 Smithkline Beecham Corp Mimetiques de la thrombopoietine
US7105824B2 (en) * 2002-05-09 2006-09-12 Neurologica, Corp. High resolution photon emission computed tomographic imaging tool
JP3927001B2 (ja) 2001-06-15 2007-06-06 三菱化学株式会社 色素セット、インクセット並びに記録方法
JP2005519878A (ja) 2001-11-30 2005-07-07 キネテク ファーマシューティカルズ，インコーポレーテッド ヒドラゾノピラゾール誘導体および治療剤としてのその使用
AU2003213673A1 (en) 2002-03-01 2003-09-16 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
MY142390A (en) 2002-05-22 2010-11-30 Glaxosmithkline Llc 3' - [(2z)-[1-(3,4-dimethylphenyl)-1,5- dihydro-3- methyl-5-0xo-4h-pyrazol-4- ylidene]hydrazino]-2' -hydroxy -[1,1' -biphenyl]-3-carboxylic acid bis-(monoethanolamine)
US7414040B2 (en) 2002-06-06 2008-08-19 Smithkline Beecham Corporation Thrombopoietin mimetics
US20060084682A1 (en) 2002-12-13 2006-04-20 Heerding Dirk A Thrombopoietin mimetics
EP1622609A4 (fr) 2003-04-29 2008-09-03 Smithkline Beecham Corp Procedes de traitement de maladies/lesions degeneratives
TW200526638A (en) 2003-10-22 2005-08-16 Smithkline Beecham Corp 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline

Also Published As

Publication number Publication date
NZ546463A (en) 2009-08-28
IS8461A (is) 2006-05-12
WO2005041867A3 (fr) 2005-10-13
US20070072922A1 (en) 2007-03-29
CN1897937B (zh) 2010-11-24
EP1684748A2 (fr) 2006-08-02
AU2004285462B2 (en) 2010-05-27
ZA200602901B (en) 2008-02-27
CA2543216A1 (fr) 2005-05-12
AR046188A1 (es) 2005-11-30
NO20062111L (no) 2006-07-18
KR20060095761A (ko) 2006-09-01
US7666857B2 (en) 2010-02-23
AU2004285462A1 (en) 2005-05-12
JP2007509159A (ja) 2007-04-12
BRPI0415704A (pt) 2006-12-19
IL174924A0 (en) 2006-08-20
WO2005041867A8 (fr) 2006-07-06
RU2379297C2 (ru) 2010-01-20
RU2006117313A (ru) 2007-11-27
CN1897937A (zh) 2007-01-17
WO2005041867A2 (fr) 2005-05-12
MXPA06004483A (es) 2006-06-20
TW200526638A (en) 2005-08-16
EP1684748A4 (fr) 2009-12-09

Similar Documents

Publication Publication Date Title
WO2005041867A3 (fr) 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'(1h-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
IN2014DN08578A (fr)
CY1109912T1 (el) 3-[(2z)-[1-(3,4-διμεθυλοφαινυλο)-1,5-διυδρο-3-μεθυλο-5-οξο-4η-πυραζολο-4-υλιδενο]υδραζινο-2’-υδροξυ-[1,1’-διφαινυλο]-3-καρβοξυλικο οξυ δι-(μονοαιθανολαμινικο)
PT1622453E (pt) Combinações de substâncias activas que têm propriedades nematicidas, insecticidas, e fungicidas e são à base de compostos de trifluorobutenilo
UA93351C2 (uk) Похідні фталазіну як інгібітори parp
DE60113936D1 (de) Verwendung von hydroxylphenyl pyruvate dioxygenase ( HPPD )
NO20072058L (no) Inhibitorer av interaksjonen mellom MDM2 og P53
CY1111050T1 (el) Φωσφονικα, μονοφωσφοναμιδικα, διφωσφοναμιδικα για την αγωγη των ιϊκων παθησεων
PA8565001A1 (es) Formas de dosificacion de liberacion inmediata que contienen dispersiones de farmaco solido
ATE281431T1 (de) Resorcin-derivate
TR200102958T2 (tr) Siklooksijenaz-2 inhibitörleri olarak 4,5-diaril-3(2H)-furanon türevleri.
PL1689232T3 (pl) Sposób ochrony materiałów
IL156774A0 (en) Inhibitors of cruzipain and other cysteine proteases
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
NO20092372L (no) Substituerte acetofenoner anvendelige som PDE4-inhibitorer
EA200701205A1 (ru) Использование полиоксипропилентерпеновых и полиоксиэтилентерпеновых соединений в эмульсионной полимеризации
MXPA02011039A (es) Combinaciones de productos activos fungicidas.
WO2006023883A3 (fr) Inhibiteurs de canal calcium de type t
BRPI0400354A (pt) Composição microbicida, e, composição de tinta
ATE345845T1 (de) Kosmetikum zur depigmentierung
ES2191621T3 (es) Tienocicloalqu(en)ilamino-1,3,5-triazinas substituidas.
WO2002024727A3 (fr) Nouveaux inhibiteurs de la formation de fibrilles d'iapp et utilisations associees
ATE398617T1 (de) Imidazoä4,5-büpyridinderivate als inhibitoren der induzierbaren no-synthase
IL171927A0 (en) Use of tyrosine kinase inhibitor to treat diabetes
HK1093433A (en) 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'(1h-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrozol-3-one choline